SG10202011660RA - Combination therapies with farnesoid x receptor (fxr) modulators - Google Patents
Combination therapies with farnesoid x receptor (fxr) modulatorsInfo
- Publication number
- SG10202011660RA SG10202011660RA SG10202011660RA SG10202011660RA SG10202011660RA SG 10202011660R A SG10202011660R A SG 10202011660RA SG 10202011660R A SG10202011660R A SG 10202011660RA SG 10202011660R A SG10202011660R A SG 10202011660RA SG 10202011660R A SG10202011660R A SG 10202011660RA
- Authority
- SG
- Singapore
- Prior art keywords
- farnesoid
- fxr
- modulators
- receptor
- combination therapies
- Prior art date
Links
- 102100038495 Bile acid receptor Human genes 0.000 title 1
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341487P | 2016-05-25 | 2016-05-25 | |
| US201662341482P | 2016-05-25 | 2016-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202011660RA true SG10202011660RA (en) | 2020-12-30 |
Family
ID=60412964
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202011660RA SG10202011660RA (en) | 2016-05-25 | 2017-05-25 | Combination therapies with farnesoid x receptor (fxr) modulators |
| SG11201810290WA SG11201810290WA (en) | 2016-05-25 | 2017-05-25 | Combination therapies with farnesoid x receptor (fxr) modulators |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810290WA SG11201810290WA (en) | 2016-05-25 | 2017-05-25 | Combination therapies with farnesoid x receptor (fxr) modulators |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200397798A1 (https=) |
| EP (1) | EP3463373A4 (https=) |
| JP (1) | JP2019517478A (https=) |
| KR (1) | KR20190040936A (https=) |
| CN (1) | CN109843298A (https=) |
| AU (1) | AU2017270221A1 (https=) |
| BR (1) | BR112018073460A2 (https=) |
| CA (1) | CA3025007A1 (https=) |
| IL (1) | IL263179A (https=) |
| MX (1) | MX2018014024A (https=) |
| RU (1) | RU2018145776A (https=) |
| SG (2) | SG10202011660RA (https=) |
| WO (1) | WO2017205684A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2019144064A (ru) * | 2017-06-02 | 2021-07-13 | Акарна Терапьютикс, Лтд. | Конденсированные бициклические соединения |
| US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
| US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
| JP2022514731A (ja) * | 2018-08-14 | 2022-02-15 | アヴォリント | 原発性硬化性胆管炎の処置方法 |
| US20210393662A1 (en) * | 2018-10-18 | 2021-12-23 | Avolynt | Use of sglt2 inhibitors to treat primary sclerosing cholangitis |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| CN111825653A (zh) * | 2019-04-19 | 2020-10-27 | 安道麦马克西姆有限公司 | 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途 |
| AU2020336272A1 (en) | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021050945A1 (en) | 2019-09-12 | 2021-03-18 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN114929214A (zh) * | 2019-11-22 | 2022-08-19 | 阿沃林特有限公司 | Sglt2抑制剂治疗原发性胆汁性胆管炎的用途 |
| CA3168474A1 (en) * | 2020-03-11 | 2021-09-16 | Mi-Kyung Kim | Pharmaceutical composition for prevention or treatment of nonalcoholic steatohepatitis |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| US20220034871A1 (en) * | 2020-07-31 | 2022-02-03 | Daiichi Sankyo Company, Limited | Methods for administering pexidartinib |
| CA3193057A1 (en) | 2020-08-25 | 2022-03-03 | Eli Lilly And Company | Polymorphs of an ssao inhibitor |
| US20240319210A1 (en) * | 2020-12-18 | 2024-09-26 | Human Metabolomics Institute, Inc. | Application of neonatal biliary atresia biomarker and detection method for same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8466143B2 (en) * | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Azepine derivatives as pharmaceutical agents |
| JP5081161B2 (ja) * | 2005-12-19 | 2012-11-21 | スミスクライン ビーチャム コーポレーション | ファルネソイドｘ受容体アゴニスト |
| ES2552657T3 (es) * | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
| EP3777863A1 (en) * | 2014-09-12 | 2021-02-17 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| CN111662297A (zh) * | 2014-11-21 | 2020-09-15 | 阿卡纳治疗学有限公司 | 用于治疗疾病的稠合双环化合物 |
| EP3715348A1 (en) * | 2015-03-26 | 2020-09-30 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
-
2017
- 2017-05-25 BR BR112018073460A patent/BR112018073460A2/pt not_active Application Discontinuation
- 2017-05-25 SG SG10202011660RA patent/SG10202011660RA/en unknown
- 2017-05-25 EP EP17803627.3A patent/EP3463373A4/en not_active Withdrawn
- 2017-05-25 CN CN201780045766.3A patent/CN109843298A/zh active Pending
- 2017-05-25 CA CA3025007A patent/CA3025007A1/en not_active Abandoned
- 2017-05-25 WO PCT/US2017/034564 patent/WO2017205684A1/en not_active Ceased
- 2017-05-25 KR KR1020187037471A patent/KR20190040936A/ko not_active Ceased
- 2017-05-25 MX MX2018014024A patent/MX2018014024A/es unknown
- 2017-05-25 US US16/303,741 patent/US20200397798A1/en not_active Abandoned
- 2017-05-25 JP JP2018562106A patent/JP2019517478A/ja active Pending
- 2017-05-25 RU RU2018145776A patent/RU2018145776A/ru not_active Application Discontinuation
- 2017-05-25 AU AU2017270221A patent/AU2017270221A1/en not_active Abandoned
- 2017-05-25 SG SG11201810290WA patent/SG11201810290WA/en unknown
-
2018
- 2018-11-21 IL IL263179A patent/IL263179A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018145776A (ru) | 2020-06-26 |
| WO2017205684A1 (en) | 2017-11-30 |
| RU2018145776A3 (https=) | 2021-03-01 |
| EP3463373A4 (en) | 2020-04-22 |
| SG11201810290WA (en) | 2018-12-28 |
| CA3025007A1 (en) | 2017-11-30 |
| AU2017270221A1 (en) | 2018-12-20 |
| BR112018073460A2 (pt) | 2019-07-09 |
| IL263179A (en) | 2018-12-31 |
| CN109843298A (zh) | 2019-06-04 |
| US20200397798A1 (en) | 2020-12-24 |
| MX2018014024A (es) | 2019-08-29 |
| EP3463373A1 (en) | 2019-04-10 |
| JP2019517478A (ja) | 2019-06-24 |
| KR20190040936A (ko) | 2019-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263179A (en) | Combination therapies with farnesoid x receptor (fxr) modulators | |
| IL282391A (en) | Allosteric modulators of hepatitis B core protein | |
| IL274407A (en) | Combined treatments | |
| ZA201802901B (en) | Farnesoid x receptor modulators | |
| IL264951B (en) | Positive allosteric modulators of the m1 muscarinic receptor | |
| ZA201605712B (en) | Therapeutic combinations with estrogen receptor modulators | |
| IL261807A (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| IL286107A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| ZA201700342B (en) | Novel glp-1 receptor modulators | |
| SG10201912456RA (en) | Combination therapies | |
| EP3423094A4 (en) | GFRAL RECEPTOR THERAPIES | |
| IL251067A0 (en) | p2x7 modulators | |
| GB201604070D0 (en) | On-premise and off-premise communication | |
| IL252565B (en) | New receptor modulators | |
| IL249203B (en) | Androgen receptor modulators and methods of using them | |
| IL255994A (en) | Muscarinic receptor modulators if 1. positive allosteric | |
| HK40006535A (en) | Combination therapies with farnesoid x receptor (fxr) modulators | |
| GB201512054D0 (en) | G-spot vibrator |